| Autor: |
Robert C. Seeger, Dean A. Lee, Laurence J.N. Cooper, Srinivas S. Somanchi, Richard Sposto, Michael A. Sheard, Hong-Wei Wu, Yin Liu |
| Rok vydání: |
2023 |
| DOI: |
10.1158/1078-0432.22452339.v1 |
| Popis: |
PDF file - 1549K, Supplemental Figure 1. Cytokine and chemokine release from K562 Clone 9.mbIL21 aAPC-expanded effector cells after 24-hour incubation with neuroblastoma cell line CHLA-255-Fluc alone or with anti-GD2 antibody ch14.18. Supplemental Figure 2. Anti-tumor activity of K562 Clone 9.mbIL21 aAPC-expanded and cryopreserved effector cells from a normal donor PBMC that were thawed and cultured for 3 days or thawed and immediately injected intravenously into NOD/SCID mice beginning 7 days after they had received 106 CHLA-255-Fluc neuroblastoma cells intravenously. Supplemental Figure 3. Anti-tumor activity of dose-dense treatment with K562 Clone 9.mbIL21 aAPC-expanded and cryopreserved aNK cells derived from a patient�s PBMC. Supplemental Figure 4. Anti-tumor activity of K562 Clone 9.mbIL21 aAPC-expanded and cryopreserved aNK cells derived from a patient�s PBMC when treatment was begun 21 days (late treatment) after tumor cell injection. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
